2025-12-13 - Analysis Report
Here's a comprehensive analysis of Eli Lilly and Co. (LLY) based on the data provided:

**1. Return Rate Comparison**

*   **Company Overview:** Eli Lilly and Co. (LLY) is a major pharmaceutical company specializing in developing and marketing medicines across various therapeutic areas.
*   **Cumulative Return:** LLY has significantly outperformed the S&P 500 (VOO).
    *   LLY: 276.74%
    *   VOO: 102.37%
*   **Divergence:** The divergence in cumulative return between LLY and VOO is substantial.
    *   Absolute Divergence (Current): 190.7
    *   Relative Divergence: 79.5 (LLY's outperformance is positioned in the top 79.5% of its historical range relative to VOO)

*   **Alpha, Beta Analysis:**

    | Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
    |------------|---------|---------|---------|--------|--------|
    | 2015-2017  | 11.0%   | 76.1%   | -17.0%  | -0.0   | 78.3   |
    | 2016-2018  | 39.0%   | 68.9%   | 24.0%   | -0.0   | 107.3  |
    | 2017-2019  | 41.0%   | 68.9%   | 19.0%   | 0.4    | 121.8  |
    | 2018-2020  | 34.0%   | 79.8%   | 10.0%   | 0.4    | 156.5  |
    | 2019-2021  | 53.0%   | 79.8%   | 7.0%    | 0.5    | 256.1  |
    | 2020-2022  | 64.0%   | 79.8%   | 65.0%   | 0.4    | 339.1  |
    | 2021-2023  | 125.0%  | 78.9%   | 124.0%  | 0.2    | 540.4  |
    | 2022-2024  | 134.0%  | 81.2%   | 113.0%  | 0.2    | 715.6  |
    | 2023-2025  | 168.0%  | 83.5%   | 101.0%  | 0.2    | 921.1  |

    *   **CAGR:** Consistently high, indicating strong growth.
    *   **MDD:** High Maximum Drawdown suggests considerable volatility, though manageable given the high CAGR.
    *   **Alpha:**  Remarkably high, indicating significant outperformance relative to its risk. The last few years show exceptionally high alpha generation.
    *   **Beta:** Relatively low Beta values suggest that LLY is less correlated with the overall market and its returns are largely independent of market movements.
    *   **Cap(B):**  The company's market capitalization has grown substantially, reflecting investor confidence and increasing valuation.

**Analysis:** LLY's strong performance is driven by its ability to generate returns independent of the broader market. The high Alpha values demonstrate a strong ability to generate returns above what would be expected based on its risk profile. While the Maximum Drawdown is considerable, the high CAGR suggests that the stock recovers well from downturns.

**2. Recent Stock Price Fluctuations**

*   **Current Price:** 993.64
*   **Last Market Data:** Price: 1027.51, Previous Close: 1009.38, Change: 1.8
*   **Simple Moving Averages (SMA):**
    *   5-day SMA: 999.65
    *   20-day SMA: 1038.3
    *   60-day SMA: 896.39

**Analysis:** The current price is below the 5-day and 20-day SMAs, suggesting a potential short-term downtrend or consolidation. The 5-day SMA is below the 20-day SMA, confirming the short-term downtrend.  The 60-day SMA is significantly lower, indicating a longer-term upward trend overall. The last market data indicates a positive price change, suggesting a recent upward movement.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 36.81 (Approaching oversold territory)
*   **PPO:** -1.76 (Negative, indicating a downtrend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90)
*   **Recent Relative Divergence Change:** -11.5 (Short-term decline)
*   **Expected Return:** 55.2% (Long-term outlook)

**Analysis:** The MRI suggests a medium investment recommendation.  The RSI is nearing oversold territory, which *could* signal a potential buying opportunity. The negative PPO supports the short-term downtrend indicated by the SMAs. The Hybrid Signal suggesting a 100% buy indicates a very positive outlook and high safety level. The recent decline in relative divergence (-11.5) confirms a short-term drop.  The Expected Return of 55.2% is highly optimistic, suggesting strong confidence in LLY's long-term growth potential. The large change in last market data ('price': 1027.51, 'previousClose': 1009.38, 'change': 1.8) reflects recent price volatility.

**4. Recent News & Significant Events**

The news headlines paint a bullish picture for Eli Lilly, primarily driven by positive data related to their obesity drug pipeline:

*   **Retatrutide Weight-Loss Data:** Significant weight loss results are driving investor excitement.
*   **Orforglipron FDA Fast-Track Questions:**  Progress with another obesity drug candidate.
*   **Analyst Forecasts & Goldman Sachs:**  Positive analyst coverage and outlook for obesity stocks.
*   **Trillion-Dollar Club Prediction:**  Suggests significant long-term growth potential.
*   **Phase 3 Obesity Drug Goals:**  Crushing expectations in clinical trials.
*   **$6B Plant Announcement**: Investments for future growth

**Analysis:** The news flow is overwhelmingly positive, focusing on the potential of LLY's obesity drug pipeline and its future growth prospects.

**4-2. Analyst Opinions**

*   **Consensus:** Strong Buy (Mean: 1.77)
*   **Target Price (Avg/High/Low):** 1075.74 / 1500.00 / 770.00

**Analysis:**  The analyst consensus is strongly bullish, with a significant average target price above the current trading price. The high target of $1500 indicates some analysts are very optimistic.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-10-30 | 6.22  | 17.60 B$   |
| 2025-08-07 | 6.3   | 15.56 B$   |
| 2025-05-01 | 3.07  | 12.73 B$   |
| 2024-10-30 | 1.08  | 11.44 B$   |
| 2025-10-30 | 1.08  | 11.44 B$   |

**Analysis:**  Earnings per share (EPS) and revenue have shown a strong upward trend over the last few quarters. The significant increase in EPS suggests improved profitability.  Note: There's a duplicate entry for 2025-10-30 with differing EPS and revenue; I'm considering the higher figures to be the accurate ones.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.60B   | 82.91%        |
| 2025-06-30   | $15.56B   | 84.27%        |
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE        |
|--------------|------------|------------|
| 2025-09-30   | $23.79B   | 23.46%     |
| 2025-06-30   | $18.27B   | 30.98%     |
| 2025-03-31   | $15.76B   | 17.50%     |
| 2024-12-31   | $14.19B   | 31.07%     |
| 2024-09-30   | $14.24B   | 6.81%      |

**Analysis:**

*   **Revenue:** Consistent and significant revenue growth over the past year.
*   **Profit Margin:** Exceptionally high and stable profit margins, indicating strong pricing power and efficient operations.
*   **Equity:** Growing equity base suggesting reinvestment of profits and balance sheet strength.
*   **ROE:**  Generally high ROE, although fluctuating, points to efficient use of equity to generate profits. The ROE figures vary significantly, indicating that the profitability of LLY's equity is influenced by quarterly factors.

**7. Comprehensive Analysis**

Eli Lilly is exhibiting strong financial performance and significant growth potential, particularly driven by its advancements in obesity treatments.

*   **Strengths:**
    *   **Exceptional Outperformance:** LLY has significantly outperformed the S&P 500.
    *   **Strong Growth:** High CAGR, revenue growth, and increasing market capitalization.
    *   **High Profitability:** High and stable profit margins and ROE.
    *   **Positive News Flow:** Driven by promising clinical trial data for obesity drugs.
    *   **Bullish Analyst Sentiment:** Strong buy consensus with high target prices.
    *   **Strong Alpha:** Ability to generate returns independent of the market
*   **Weaknesses:**
    *   **High Volatility:** Significant MDD indicates potential price swings.
    *   **Short-Term Downtrend:** Recent price action and technical indicators suggest a possible short-term pullback.
    *   **Inconsistent ROE:** Significant variations in ROE suggest fluctuations in the company's profitability quarter to quarter.
*   **Opportunities:**
    *   **Obesity Drug Market:** Significant market potential for LLY's drug pipeline.
    *   **Long-Term Growth:** Potential for further expansion and increased profitability.
*   **Risks:**
    *   **Clinical Trial Risks:**  Potential for setbacks in drug development.
    *   **Competition:** Increasing competition in the obesity drug market.
    *   **Market Volatility:** General market downturns could negatively impact the stock price.

**Overall Recommendation:**

Based on the data provided, Eli Lilly appears to be a strong investment with significant long-term growth potential. The short-term downtrend and volatility should be considered, but the company's strong fundamentals, positive news flow, and bullish analyst sentiment suggest that LLY is well-positioned for continued success. However, it is important to conduct thorough due diligence and consider your personal risk tolerance before making any investment decisions. The high growth in a specific area (obesity drugs) makes the company susceptible to any adverse events in that particular sector.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.